埃索美拉唑
兰索拉唑
烧心
医学
奥美拉唑
内科学
胃肠病学
耐受性
格尔德
随机对照试验
质子抑制剂泵
回流
不利影响
疾病
作者
M. Brian Fennerty,John F. Johanson,Clara Hwang,Mark Sostek
标识
DOI:10.1111/j.1365-2036.2005.02339.x
摘要
Summary Background : Secondary analyses from previous studies indicated that esomeprazole was more effective than lansoprazole and omeprazole in healing moderate or severe (Los Angeles grades C or D) erosive oesophagitis (EE). Aim : To compare prospectively healing rates with esomeprazole vs. lansoprazole in patients with moderate to severe EE. Methods : In this multicentre, randomized, double‐blind, parallel‐group trial, adult patients with endoscopically confirmed moderate or severe EE received esomeprazole 40 mg ( n = 498) or lansoprazole 30 mg ( n = 501) once daily for up to 8 weeks. The primary end point was EE healing through week 8. Secondary assessments included investigator‐assessed resolution of symptoms and safety and tolerability. Results : Time to healing was significantly different ( P = 0.007), favouring esomeprazole. Estimated healing rates at week 8 were 82.4% with esomeprazole 40 mg and 77.5% with lansoprazole 30 mg. Heartburn resolved at week 4 in 72% and 64% of patients who received esomeprazole and lansoprazole, respectively ( P = 0.005). Control of other GERD symptoms was similar between treatments. Both treatments were well tolerated. Conclusions : With 8 weeks’ treatment, esomeprazole 40 mg once daily heals moderate to severe EE faster and in more patients, and resolves heartburn in more patients after 4 weeks of treatment, than lansoprazole 30 mg once daily.
科研通智能强力驱动
Strongly Powered by AbleSci AI